Cargando…

Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment

Neutrophils, the most abundant leukocytes in human blood, are essential fighter immune cells against microbial infection. Based on the finding that neutrophils can either restrict or promote cancer progression, tumor-associated neutrophils (TAN) are classified into anti-tumor N1 and pro-tumor N2 sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuting, Guoqiang, Liu, Sun, Miaomiao, Lu, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142839/
https://www.ncbi.nlm.nih.gov/pubmed/32296575
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0372
_version_ 1783519473823645696
author Zhang, Yuting
Guoqiang, Liu
Sun, Miaomiao
Lu, Xin
author_facet Zhang, Yuting
Guoqiang, Liu
Sun, Miaomiao
Lu, Xin
author_sort Zhang, Yuting
collection PubMed
description Neutrophils, the most abundant leukocytes in human blood, are essential fighter immune cells against microbial infection. Based on the finding that neutrophils can either restrict or promote cancer progression, tumor-associated neutrophils (TAN) are classified into anti-tumor N1 and pro-tumor N2 subsets. One of the major mechanisms underlying the tumor-promoting function of N2-TANs is suppression of adaptive immune cells, in particular, cytotoxic T lymphocytes. Currently, no established methodologies are available that can unequivocally distinguish immunosuppressive TANs and granulocytic/polymorphonuclear myeloid-derived suppressor cells (G/PMN-MDSC). In view of the critical role of PMN-MDSCs in immune evasion and resistance to cancer immunotherapy, as established from data obtained with diverse cancer models, therapeutic strategies targeting these cells have been actively developed to enhance the efficacy of immunotherapy. Here, we have reviewed the available literature on strategies targeting PMN-MDSCs and summarized the findings into four categories: (1) depletion of existing PMN-MDSCs, (2) blockade of the development of PMN-MDSCs, (3) blockade of PMN-MDSC recruitment, (4) inhibition of immunosuppressive function. Owing to their high mobility to inflamed organs and ability to trespass the blood-brain barrier, neutrophils are outstanding candidate carriers in nanoparticle-based therapies. Another attractive application of neutrophils in cancer therapy is the use of neutrophil membrane-derived nanovesicles as a surrogate of extracellular vesicles for more efficient and scalable drug delivery. In the second part of the review, we have highlighted recent advances in the field of neutrophil-based cancer drug delivery. Overall, we believe that neutrophil-based therapeutics are a rapidly growing area of cancer therapy with significant potential benefits.
format Online
Article
Text
id pubmed-7142839
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Compuscript
record_format MEDLINE/PubMed
spelling pubmed-71428392020-04-15 Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment Zhang, Yuting Guoqiang, Liu Sun, Miaomiao Lu, Xin Cancer Biol Med Review Neutrophils, the most abundant leukocytes in human blood, are essential fighter immune cells against microbial infection. Based on the finding that neutrophils can either restrict or promote cancer progression, tumor-associated neutrophils (TAN) are classified into anti-tumor N1 and pro-tumor N2 subsets. One of the major mechanisms underlying the tumor-promoting function of N2-TANs is suppression of adaptive immune cells, in particular, cytotoxic T lymphocytes. Currently, no established methodologies are available that can unequivocally distinguish immunosuppressive TANs and granulocytic/polymorphonuclear myeloid-derived suppressor cells (G/PMN-MDSC). In view of the critical role of PMN-MDSCs in immune evasion and resistance to cancer immunotherapy, as established from data obtained with diverse cancer models, therapeutic strategies targeting these cells have been actively developed to enhance the efficacy of immunotherapy. Here, we have reviewed the available literature on strategies targeting PMN-MDSCs and summarized the findings into four categories: (1) depletion of existing PMN-MDSCs, (2) blockade of the development of PMN-MDSCs, (3) blockade of PMN-MDSC recruitment, (4) inhibition of immunosuppressive function. Owing to their high mobility to inflamed organs and ability to trespass the blood-brain barrier, neutrophils are outstanding candidate carriers in nanoparticle-based therapies. Another attractive application of neutrophils in cancer therapy is the use of neutrophil membrane-derived nanovesicles as a surrogate of extracellular vesicles for more efficient and scalable drug delivery. In the second part of the review, we have highlighted recent advances in the field of neutrophil-based cancer drug delivery. Overall, we believe that neutrophil-based therapeutics are a rapidly growing area of cancer therapy with significant potential benefits. Compuscript 2020-02-15 2020-02-15 /pmc/articles/PMC7142839/ /pubmed/32296575 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0372 Text en Copyright: © 2020, Cancer Biology & Medicine http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Zhang, Yuting
Guoqiang, Liu
Sun, Miaomiao
Lu, Xin
Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment
title Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment
title_full Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment
title_fullStr Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment
title_full_unstemmed Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment
title_short Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment
title_sort targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142839/
https://www.ncbi.nlm.nih.gov/pubmed/32296575
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0372
work_keys_str_mv AT zhangyuting targetingandexploitationoftumorassociatedneutrophilstoenhanceimmunotherapyanddrugdeliveryforcancertreatment
AT guoqiangliu targetingandexploitationoftumorassociatedneutrophilstoenhanceimmunotherapyanddrugdeliveryforcancertreatment
AT sunmiaomiao targetingandexploitationoftumorassociatedneutrophilstoenhanceimmunotherapyanddrugdeliveryforcancertreatment
AT luxin targetingandexploitationoftumorassociatedneutrophilstoenhanceimmunotherapyanddrugdeliveryforcancertreatment